Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
AMRN is in the long-term up 420% in 3 years.
Description: Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases in the United States. It develops products in the areas of lipid science and therapeutic benefits of polyunsaturated fatty acids. The company markets Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It is also developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-0.33||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||26.39%||Sales Growth - Q/Q||-3.32%||P/E||-8.88|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-28.56%||ROE||99.49%||ROI||-38.89%|
|Current Ratio||4.46||Quick Ratio||4.08||Long Term Debt/Equity||1.49||Debt Ratio||-0.69|
|Gross Margin||63.04%||Operating Margin||-164.67%||Net Profit Margin||-103.96%||Dividend Payout Ratio|
|Cash From Financing Activities||54.3 M||Cash From Investing Activities||Cash From Operating Activities||-12.64 M||Gross Profit||10.31 M|
|Net Profit||-31.13 M||Operating Profit||-27.05 M||Total Assets||215.34 M||Total Current Assets||189.75 M|
|Total Current Liabilities||42.53 M||Total Debt||233.48 M||Total Liabilities||277.16 M||Total Revenue||15.93 M|
|High 52 week||23.16||Low 52 week||12.41||Last close||15.86||Last change||2.65%|
|RSI||49.7||Average true range||0.66||Beta||0.52||Volume||2.65 M|
|Simple moving average 20 days||3.48%||Simple moving average 50 days||1.83%||Simple moving average 200 days||-10.53%|
|Performance Week||12.08%||Performance Month||-8.06%||Performance Quart||-24.73%||Performance Half||-13.76%|
|Performance Year||-19.29%||Performance Year-to-date||16.53%||Volatility daily||2.47%||Volatility weekly||5.52%|
|Volatility monthly||11.31%||Volatility yearly||39.17%||Relative Volume||527.59%||Average Volume||7.79 M|
|New High||New Low|
2019-11-15 16:32:08 | This Biotech Stock Broke Out Bullishly On A Key FDA Recommendation
2019-11-15 15:04:19 | Analyst: Peak Sales Potential Of Amarin's Vascepa Underappreciated
2019-11-15 09:47:28 | Amarin Stock Jumps as Debate Moves to Heart Drug’s Potential Label
2019-11-15 09:22:08 | This Fish-Oil Heart Drug Will Be Big, Could Be Huge
2019-11-15 09:10:02 | Amarin AMRN Gets FDA Panel Nod for Vascepa Label Expansion
2019-11-15 08:54:00 | Amarin Stock Is Rising After Favorable Vote on Fish-Based Heart Drug
2019-11-15 08:25:00 | Amarin shares rise in premarket trading on FDA adcom vote for new label
2019-11-15 06:30:00 | HLS Therapeutics Reports on U.S. FDA Advisory Committee Recommendation for Vascepa
2019-11-14 17:34:37 | Amarin Announced FDA Advisory Committee Voted Unanimously 16-0 to Recommend Approval of Vascepa® icosapent ethyl Capsules Label Expansion to Reduce Cardiovascular Risk Based on Landmark REDUCE-IT® Outcomes Trial
2019-11-14 17:03:25 | Will A Positive FDA Committee Vote Send This Biotech Into A Breakout?
2019-11-14 16:59:00 | Amarin’s Fish-Based Cardiovascular Drug Gets Thumbs Up From FDA Committee
2019-11-14 16:32:08 | Amarin Wins FDA Panel Nod to Expand Heart Drug Vascepa’s Label
2019-11-14 16:30:18 | UPDATE 2-FDA panel unanimously backs expanding use of Amarin's heart drug Vascepa
2019-11-14 15:05:15 | Amarin's Vascepa Adcom Meeting: What You Need To Know
2019-11-14 13:27:00 | AMD, Amarin and Crispr are three stocks to watch for potentially higher prices
2019-11-14 08:18:00 | Amarin Stock Trading Is Halted for FDA Meeting on Fish-Based Cardiovascular Drug
2019-11-14 07:23:00 | Amarin shares halted ahead of FDA committee meeting for its only drug
2019-11-14 06:59:25 | Amarin Corporation plc NASDAQ:AMRN Stock Trading Halted Today for Scheduled FDA Advisory Committee Review of sNDA Seeking New Indication for Vascepa® Icosapent Ethyl to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark REDUCE-IT® Ca
2019-11-13 15:43:08 | Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates
2019-11-13 10:38:00 | Amarin’s Cardiovascular Drug Faces a Key Test Tomorrow. What It Means for the Stock.
2019-11-13 10:00:03 | What Makes Amarin AMRN a Strong Momentum Stock: Buy Now?
2019-11-12 16:00:01 | This Biotech Just Gapped Up As FDA Mulls A Second Use For Its Medicine
2019-11-12 15:48:03 | 5 Top Stock Trades for Wednesday: SPY, DIS, PYPL
2019-11-12 14:41:00 | Amarin shares rise 21% ahead of FDA committee meeting for its only drug
2019-11-12 11:28:44 | Amarin Shares Climb Following In-Line Review Of Fish Oil Pill By FDA Staffers
2019-11-12 10:03:00 | Shares of Amarin rise on favorable opinion from FDA committee
2019-11-12 08:45:03 | Benzinga Pro's Top 5 Stocks To Watch For Tues., Nov. 12, 2019: BUD, AMRN, ROK, OGI, LK
2019-11-11 13:19:57 | New Analysis Shows Icosapent Ethyl Vascepa® Is Cost Effective and Offers Rare Finding of Better Outcomes at Lower Healthcare Costs When Used to Treat High-Risk Patients with Cardiovascular Disease or Diabetes and Other Risk Factors
2019-11-11 06:30:48 | REDUCE-IT® USA Results, in Prespecified Subgroup Analyses of Landmark REDUCE-IT Global Study, Showed Robust Cardiovascular Risk Reductions Across a Variety of Study Endpoints, Including Cardiovascular Death and All-Cause Mortality
2019-11-11 05:00:00 | Amarin to Present at the Jefferies 2019 London Healthcare Conference
2019-11-08 09:30:02 | Has Amarin Corporation AMRN Outpaced Other Medical Stocks This Year?
2019-11-05 20:09:14 | Edited Transcript of AMRN earnings conference call or presentation 5-Nov-19 12:30pm GMT
2019-11-05 05:30:00 | Amarin Corp. Plc to Host Earnings Call
2019-11-05 05:00:00 | Amarin Reports Third Quarter 2019 Financial Results and Provides Update on Operations
2019-11-04 11:42:04 | What's in the Cards for Zynerba ZYNE This Earnings Season?
2019-11-04 06:00:00 | Seven Data Presentations Relevant to Vascepa® Icosapent Ethyl Capsules and Persistent Cardiovascular Risk to be Presented at American Heart Association’s 2019 Scientific Sessions, November 16 – 18
2019-11-01 10:41:02 | What's in the Cards for Perrigo PRGO This Earnings Season?
2019-10-31 17:50:09 | Amarin AMRN Gains As Market Dips: What You Should Know
2019-10-29 10:25:02 | Is a Beat in Store for Amarin AMRN This Earnings Season?
2019-10-25 11:32:03 | Implied Volatility Surging for Amarin AMRN Stock Options
2019-10-24 16:30:05 | Amarin to Report Third Quarter 2019 Results and Host Conference Call on November 5, 2019
2019-10-24 15:57:22 | 5 'Strong Buy' Biotech Stocks With Rapidly Approaching Catalysts
2019-10-23 10:23:00 | Hedge Funds Have Never Been More Bullish On Amarin Corporation AMRN